Internationale standarisatie op komst schildkliertesten ??

Hier kan je posten en discussiëren over behandeling van schildklierstoornissen in het algemeen en jezelf in het bijzonder.

Internationale standarisatie op komst schildkliertesten ??

Berichtdoor ineke » maandag 17 mei 2010 - 19:22

Ik weet niet waar ik dit topic moet plaatsen, daarom hier.

Enige tijd geleden is een internationale standarisatie gekomen voor de HbA1C.

Nu wordt er via diverse internetbronnen aangegeven dat er
een internationale standarisatie op komst is voor de schildklierfunctie-testen.

Zie:
Standardisation of Thyroid Function Tests (WG-STFT)

Terms of Reference
•Development of reference measurement systems for thyroid hormones (free T4 & T3, TSH)
Current Projects
•Development of reference measurement systems for validation/standardization of IVD assays: proof-of-concept study for free T4
•Investigation of harmonization of TSH measurements by master comparisons

http://www.ifcc.org/index.asp?cat=Scien ... s_(WG-STFT)&zip=1&dove=1&numero=62


Alle standarisaties:
Standardisation of Hemoglobin A1c (WG-HbA1c)
Standardisation of Thyroid Function Tests (WG-STFT)
Standardisation of Hemoglobin A2 (WG-HbA2)
Standardisation of Carbohydrate-Deficient Transferrin (WG-CDT)
Standardisation of Cystatin C (WG-SCC)
Standardisation of Glomerular Filtration Rate Assessment (WG-GFRA)
Standardisation of Albumin Assay in Urine (WG-SAU)
Standardisation of Pregnancy-Associated Plasma Protein A (WG-PAPPA)
Growth Hormone (WG-GH)
Standardization of Insulin Assays (WG-SIA)
Standardization of Troponin I (WG-TNI)
Allowable Errors for Traceable Results (WG-AETR)
Harmonisation of Autoantibody Tests (WG-HAT)
Quality Specifications for Glucose POCT (WG-GPOCT)

Link:
http://www.ifcc.org/index.asp?cat=Scien ... f=4&dove=1



Via Pubmed:
Report of the IFCC Working Group for Standardization of Thyroid Function Tests, Part 1:
Thyroid-Stimulating Hormone.

http://www.ncbi.nlm.nih.gov/pubmed/20395624

Report of the IFCC Working Group for Standardization of Thyroid Function Tests, Part 2:
Free Thyroxine and Free Triiodothyronine

http://www.ncbi.nlm.nih.gov/pubmed/20395623

Report of the IFCC Working Group for Standardization of Thyroid Function Tests, Part 3:
Total Thyroxine and Total Triiodothyronine.

http://www.ncbi.nlm.nih.gov/pubmed/20395622
Groeten, Ineke
Avatar gebruiker
ineke
Forumverslaafde
 
Berichten: 1378
Geregistreerd: zaterdag 17 juni 2006 - 14:12

Berichtdoor ineke » zaterdag 28 augustus 2010 - 12:57

Hieronder informatie van de AACC
(2010 American Association for Clinical Chemistry)


Hieronder betreft de geschreven tekst van een podcast van juni 2010.
zie beide linken onder deze quote.

Tekst
IFCC Working Group for Standardization of Thyroid Function Tests

Een paar stukjes:
But first of all, with the implementation of the work in mind, we sought a broad representation of stakeholders in our group.
This was achieved by appointing members from the academic world, metrological institutes, producers of reference materials, the in vitro diagnostic industry, and last but not least, from the International Thyroid Associations.

Second, work was undertaken to lay the metrological foundation to standardization, which is based on a complete reference measurement system, which is preferably an SItraceable system, and comprising the measurant, reference materials, reference measurement procedures, and routine procedures.

And in the conviction that the reference measurement system needs international recognition, close cooperation with the Joint Committee for Traceability in Laboratory Medicine is required.
The abbreviation for that committee is JCTLM.

The JCTLM is indeed a worldwide platform to promote and give guidance on internationally recognized and accepted equivalence and traceability of measurements in laboratory medicine.
Making the link to the JCTLM was rather easy for our Working Group because I head the co-chair in one of the JCTLM Working Groups.

So what metrological tools were available at the start?
Well, only for total thyroid hormones was a complete SI-traceable
reference measurement system available.
In addition, the reference materials and isotope dilution, liquid
chromatography–tandem mass spectrometry reference measurement procedures were already listed in the database of the JCTLM.

For free thyroid hormones, the working group proposed to define operation and the measurant as T4 or T3 and a dialysate from equilibrium dialysis of serum or plasma prepared under defined conditions.

For the technical realization of the measurant at a hierarchically higher order, our Working Group chose the concept of an international conventional reference measurement procedure.
The convention was about the condition for equilibrium dialysis, but the quantification of the hormone in the dialysate was to be done with an isotope dilution mass spectrometry reference measurement
procedure.

Finally, for TSH measurement, the only metrological tool that was available was immunoanalysis, and because of the heterogeneity of this glycoprotein hormone, this is really mixture analysis,  expressed in international units, defined by reference preparation from the World Health Organization.

When one looks into the three papers, one will see a great span in overall quality.
To give an example,
the total imprecision of the total T4 assays ranges from roughly 3-9%;
for free T4, from 1.5-14%;
for TSH, from 2.5-8%.
Well therefore, I think it is a great mistake to argue about the quality of, for example, free T4 immunoassays in general, because as you have seen from these figures, there are good ones as well as assays that need improvement


Okay. Well, coming to the standardization issue, could you comment on the standardization status of the different thyroid assays and the impact standardization would have?
And could you briefly also describe the process of standardization?


Dr. Linda Thienpont:
For total T4, our studies showed that the mean of the results from all immunoassays compared well with the IDMS reference method values.
In other words, the two high values seemed to balance the two lower ones.
In consequence, it is now the responsibility of the individual manufacturers to eliminate the assay-specific biases.
To solve this problem, manufacturers should follow the normal rule towards establishing traceability, which is cooperation with the JCTLM listed reference laboratory.

For total T3, the situation was quite different.
Standardization would cause a shift of the whole market to lower values.
Current values would decrease in average by roughly 15%.


(00:14:56)
For free hormones, the situation was even more pronounced, quite a the difference among the assays was seen and all were negatively biased in comparison to equilibrium dialysis mass spectrometry.
In consequence, standardization of free thyroid hormones will require a huge effort and will have a major clinical impact.

For free T3, the values would increase in average by roughly 15% but as for free T4, even by 35%.
The TSH was special in a sense.
It was amazing to see the agreement of so many assays, but very unfortunate to see that three assays caused up to 40% difference in results on average, even more pronounced in the low range.

One may question, whether this observation is clinically relevant?
Personally, I think it is.
The problem with TSH is that so called universal cut-off are used for defining subclinical hypothyroidism, mainly around about five milli international units per liter.
However, as the market is not standardized, assay specific rather than universal values should be used.

Also the discussion about lowering this value to 3 or even 2.5 milli international units per liter does not address this standardization problem.
In my opinion, it is one of the tragedies that these discussions neglect the standardization problems

(00:20:00)
Also, a much greater variety of challenging samples shall be included to explore the full impact of standardization, for example, specimens obtained from different patient categories or individuals with different pathologies, thyroid pathologies, and others and/or patients and the therapy.

This is of particular importance for standardization of free thyroid hormones and TSH measurements.
For the latter, there is indeed evidence of different glycoforms associated with hypothyroidism.

Thus, we really have to investigate whether certain assays perform differently with clinical samples.

Another point of concern for our working group is that it cannot be overlooked that standardization,
for example, of free thyroid hormone immunoassays
will cause a shift of the whole market to higher values, for some even by a factor of two
.


Gehele pdf:
http://www.aacc.org/events/podcast/docu ... enpont.pdf

Podcast:
http://media.aacc.org/CCJPodcasts/062010Holick.mp3
Groeten, Ineke
Avatar gebruiker
ineke
Forumverslaafde
 
Berichten: 1378
Geregistreerd: zaterdag 17 juni 2006 - 14:12

Berichtdoor ineke » woensdag 24 november 2010 - 16:10

Hieronder een uitgebreid artikel over dit onderwerp.


Standardization activities in the field of thyroid function tests:
a status report


Linda M. Thienpont*, Katleen Van Uytfanghe and Sofie Van Houcke
on behalf of the IFCC Working Group for Standardization of Thyroid Function Tests (WG-STFT)
Laboratory for Analytical Chemistry, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium

Abstract
Background:
Laboratory testing is an essential tool for diagnosis and management of thyroid diseases.
However, the current status of standardization hampers the interchangeability of results.
To improve this situation, the Working Group for Standardization of Thyroid Function Tests was established.

Methods:
Method comparisons were organized for measurement of human thyroid stimulating hormone (TSH), and free and total thyroid hormone in serum from apparently healthy donors.
The aim was to assess the status of standardization and the quality of the performance of current routine assays.
A second objective was to investigate the effect of mathematical
recalibration of the results using their relationship to the overall mean (TSH) or the reference measurement procedure values (other thyroid hormones

Results:
The need for standardization was shown to be highest for free thyroid hormone and total triiodothyronine measurements, while the majority of TSH and total thyroxine assays agreed within 10% of the reference.
Most assays showed good performance.
However, some could benefit from improved precision, consistency of calibration, or within- and between-run stability.
Recalibration eliminated assayspecific bias.
Thus, the residual spread was due to withinmethod effects.
Not withstanding, sample-related effects remained.

Conclusions:
These studies confirmed the feasibility of standardization
based on method comparison with native sera, but highlighted the need to resolve issues, such as samplerelated effects.
In view of the fact that in this phase the project worked with samples from individuals with euthyroid status, the next method comparison shall place emphasis on challenging the performance of the assays with clinical samples and expanding the covered measurement range.
Clin Chem Lab Med 2010;48:1577–83.

Introduction
The prevalence of thyroid dysfunction in adults in the general
population ranges from 4% to 8%.
It is even higher in selected groups, such as elderly women, or young females postpartum (e.g., 1–7).
This prevalence explains why the worldwide yearly volume of requests for testing of human thyroid stimulating hormone (TSH) and free thyroxine (FT4) is estimated to be in the order of 180 and 60 million, respectively (C. Weinzierl, Beckman-Coulter, personal communication).
Although it is believed that  zie de rest via de link

Figure 1
Box and Whisker plot representing the status of standardization of the TSH, FT4, FT3, TT4 and TT3 assays participating in the first method comparison study.

For TSH and FT4, the second box (labeled by *) represents the status observed in the proof-of-concept study.
The ordinate represents the % difference from the overall mean (TSH), the conventional RMPs (FT4, FT3) and the SI-traceable RMPs (TT4, TT3).

Table 1
Numerical data describing the differences (%) shown in the Box and Whisker plot in Figure 1.

Figure 2
Box and Whisker plot showing the post-recalibration status of the examined assays.
The results of all assays were mathematically recalibrated using the reverse regression equation applying for each individual assay’s method comparison data.
For TSH and FT4, the second box (labeled by *) shows recalibration by the manufacturers on the basis of the master calibrators.

Table 2
Representative data for performance quality of the examined assays in the first method comparison (26–28).
TSH FT4 FT3 TT4 TT3


http://www.reference-global.com/doi/pdf ... M.2010.321
Groeten, Ineke
Avatar gebruiker
ineke
Forumverslaafde
 
Berichten: 1378
Geregistreerd: zaterdag 17 juni 2006 - 14:12

Berichtdoor ineke » woensdag 24 november 2010 - 16:27

Hieronder nog een rapport van de WHO over TSAb

EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION
Geneva, 18 to 22 October 2010

WHO International Collaborative Study of the
proposed 2nd International Standard for Thyroid Stimulating Antibody

Introduction
Thyroid-stimulating hormone receptor (TSHR) autoantibodies (TRAb) are important in the pathogenesis of autoimmune hyperthyroidism and comprise thyroid-stimulating antibodies and
thyroid-blocking antibodies (reviewed in 1).
Thyroid-stimulating antibodies (TSAbs) can be
detected in the vast majority of patients with hyperthyroidism caused by Graves’ disease and
have also been associated with a small portion of patients with toxic multinodular goitre. These
autoantibodies interact with the TSH receptor on thyroid follicular cells and usually result in
global stimulation of thyroid activity. Measurements of TSAbs are useful in the diagnosis and
management of disease. For example, the detection of TSAbs has been used to predict relapse or
remission in patients receiving treatment for Graves’ disease, and also to predict neonatal
hyperthyroidism in children of mothers with Graves’ disease. The original preparation of 90/672,
stocks of which are now exhausted, consisted of freeze-dried plasma proteins from a single
human patient with high TSAb levels who was pregnant and whose plasma was regularly
exchanged by plasmapheresis during pregnancy. This preparation was established by the WHO
Expert Committee on Biological Standardization in 1995 and was itself calibrated in terms of
MRC research standard B for long-acting thyroid stimulator (MRC LATS B, coded 65/122) and
in terms of local standards. Although, the preparation was deemed suitable for the calibration of
both bioassays and receptor assays for the measurement of autoantibodies to the TSH receptor,
the significant differences between 90/672 and 65/122 in terms of bioassay and receptor assay
unitage meant that the ampoule content of 90/672 did not represent a formal continuity of
unitage with 65/122 and the relationship between the unitage of the two standards was dependent
on the assay system employed. In addition it was noted that since 90/672 was derived from a
single patient, it may not be qualitatively suitable to serve as a standard for all TSAb samples.
Despite these limitations, 90/672 has been widely used for the calibration of assays to measure
TSH receptor autoantibodies in human serum. In 2006, the World Health Organization (WHO)
Expert Committee on Biological Standardization (ECBS) recognized the

Conclusions and recommendations
The clinical measurement of stimulatory autoantibodies to the TSHR is useful for the
confirmation of Graves’ disease and Graves’ opthalmopathy, the differential diagnosis of
Graves’ diseases from other causes of hyperthyroidism and the prediction of neonatal
thyrotoxicosis in pregnant women with Graves’ disease. Although functional bioassays are the
gold standard in basic science research and in some rare clinical cases, the second and third
generation receptor binding assays based on the competition of patient autoantibodies and
labelled TSH/M22 for binding sites on the TSHR are more widely

zie de rest via deze link:
http://www.who.int/biologicals/expert_c ... tibody.pdf
Groeten, Ineke
Avatar gebruiker
ineke
Forumverslaafde
 
Berichten: 1378
Geregistreerd: zaterdag 17 juni 2006 - 14:12


Keer terug naar Behandeling algemeen

Wie is er online

Gebruikers op dit forum: Geen geregistreerde gebruikers. en 1 gast